Format

Send to

Choose Destination
Methods Mol Biol. 2016;1403:269-84. doi: 10.1007/978-1-4939-3387-7_14.

Development of a SARS Coronavirus Vaccine from Recombinant Spike Protein Plus Delta Inulin Adjuvant.

Author information

1
Protein Sciences Corporation Inc, Meriden, CT, USA.
2
Vaxine Pty Ltd, 1 Flinders Drive, Bedford Park, Adelaide, 5042, Australia.
3
Institute for Antiviral Research, Utah State University, 5600 Old Main Hill, Logan, UT, 84322-560, USA.
4
Vaxine Pty Ltd, 1 Flinders Drive, Bedford Park, Adelaide, 5042, Australia. nikolai.petrovsky@flinders.edu.au.
5
Department of Diabetes and Endocrinology, Flinders University, Adelaide, SA, 5042, Australia. nikolai.petrovsky@flinders.edu.au.

Abstract

Given periodic outbreaks of fatal human infections caused by coronaviruses, development of an optimal coronavirus vaccine platform capable of rapid production is an ongoing priority. This chapter describes the use of an insect cell expression system for rapid production of a recombinant vaccine against severe acute respiratory syndrome coronavirus (SARS). Detailed methods are presented for expression, purification, and release testing of SARS recombinant spike protein antigen, followed by adjuvant formulation and animal testing. The methods herein described for rapid development of a highly protective SARS vaccine are equally suited to rapid development of vaccines against other fatal human coronavirus infections, e.g., the MERS coronavirus.

KEYWORDS:

Adjuvant; Advax adjuvant; Baculovirus; Coronavirus; Delta inulin; MERS; Manufacture; SARS; Vaccine; cGMP

PMID:
27076136
DOI:
10.1007/978-1-4939-3387-7_14
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center